[1] Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, et al.  Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71: 209-249.   doi: 10.3322/caac.21660
[2] 叶定伟, 朱耀.  中国前列腺癌的流行病学概述和启示[J]. 中华外科杂志, 2015, 53(4): 249-252.   doi: 10.3760/cma.j.issn.0529-5815.2015.04.003
Ye DW, Zhu Y.  Epidemiology of prostate cancer in China: an overview and clinical implication[J]. Chin J Surg, 2015, 53(4): 249-252.   doi: 10.3760/cma.j.issn.0529-5815.2015.04.003
[3] Mohler JL, Antonarakis ES, Armstrong AJ, et al.  Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2019, 17(5): 479-505.   doi: 10.6004/jnccn.2019.0023
[4] Satapathy S, Singh H, Kumar R, et al.  Diagnostic accuracy of 68Ga-PSMA PET/CT for initial detection in patients with suspected prostate cancer: a systematic review and meta-analysis[J]. AJR Am J Roentgenol, 2021, 216(3): 599-607.   doi: 10.2214/AJR.20.23912
[5] Brito AET, Mourato FA, de Oliveira RPM, et al.  Evaluation of whole-body tumor burden with 68Ga-PSMA PET/CT in the biochemical recurrence of prostate cancer[J]. Ann Nucl Med, 2019, 33(5): 344-350.   doi: 10.1007/s12149-019-01342-z
[6] Demirci E, Kabasakal L, Şahin OE, et al.  Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?[J]. Nucl Med Commun, 2019, 40(1): 86-91.   doi: 10.1097/MNM.0000000000000942
[7] Basha MAA, Hamed MAG, Hussein O, et al.  68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement[J]. Abdom Radiol (NY), 2019, 44(7): 2545-2556.   doi: 10.1007/s00261-019-02006-2
[8] Meyrick DP, Asokendaran M, Skelly LA, et al.  The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer[J]. Nucl Med Commun, 2017, 38(11): 956-963.   doi: 10.1097/MNM.0000000000000738
[9] Uprimny C, Kroiss AS, Decristoforo C, et al.  68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour[J]. Eur J Nucl Med Mol Imaging, 2017, 44(6): 941-949.   doi: 10.1007/s00259-017-3631-6
[10] Ergül N, Burçak YG, Yücetaş U, et al.  68Ga-PSMA-11 PET/CT in newly diagnosed prostate adenocarcinoma[J]. Clin Nucl Med, 2018, 43(12): e422-e427.   doi: 10.1097/RLU.0000000000002289
[11] Schmuck S, von Klot CA, Henkenberens C, et al.  Initial experience with volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer[J]. J Nucl Med, 2017, 58(12): 1962-1968.   doi: 10.2967/jnumed.117.193581
[12] Schmidkonz C, Cordes M, Schmidt D, et al.  68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2018, 45(11): 1862-1872.   doi: 10.1007/s00259-018-4042-z
[13] Etchebehere EC, Araujo JC, Fox PS, et al.  Prognostic factors in patients treated with 223Ra: the role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival[J]. J Nucl Med, 2015, 56(8): 1177-1184.   doi: 10.2967/jnumed.115.158626
[14] Liu C, Liu TL, Zhang N, et al.  68Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients[J]. Eur J Nucl Med Mol Imaging, 2018, 45(11): 1852-1861.   doi: 10.1007/s00259-018-4037-9
[15] Kuroda K, He L.  The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor[J]. Int J Oncol, 2019, 54(4): 1357-1366.   doi: 10.3892/ijo.2019.4706
[16]

von Eyben FE, Picchio M, von Eyben R, et al. 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis[J/OL]. Eur Urol Focus, 2018, 4(5): 686−693[2020-09-01]. https://www.eu-focus.europeanurology.com/article/S2405-4569(16)30160-2/fulltext. DOI: 10.1016/j.euf.2016.11.002.
[17] Koerber SA, Utzinger MT, Kratochwil C, et al.  68Ga-PSMA-11 PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters[J]. J Nucl Med, 2017, 58(12): 1943-1948.   doi: 10.2967/jnumed.117.190314
[18]

Ruigrok EAM, van Weerden WM, Nonnekens J, et al. The future of PSMA-targeted radionuclide therapy: an overview of recent preclinical research[J/OL]. Pharmaceutics, 2019, 11(11): 560[2020-09-01]. https://www.mdpi.com/1999-4923/11/11/560. DOI: 10.3390/pharmaceutics11110560.
[19]

Schollhammer R, De Clermont Gallerande H, Yacoub M, et al. Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples[J/OL]. EJNMMI Res, 2019, 9(1): 52[2020-09-01]. https://ejnmmires.springeropen.com/articles/10.1186/s13550-019-0517-6. DOI: 10.1186/s13550-019-0517-6.
[20] Fankhauser CD, Poyet C, Kroeze SGC, et al.  Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer[J]. World J Urol, 2019, 37(3): 457-467.   doi: 10.1007/s00345-018-2408-2